Improvement of renal function by changing the bone-modifying agent from zoledronic acid to denosumab (Q37443111)

20 August 2017

Improvement of renal function by changing the bone-modifying agent from zoledronic acid to denosumab (English)

1 reference

20 August 2017

1 reference

Mutsushi Yamasaki

1 reference

20 August 2017

Takeshi Yuasa

1 reference

20 August 2017

Sho Uehara

1 reference

20 August 2017

Yasuhisa Fujii

1 reference

20 August 2017

Shinya Yamamoto

1 reference

20 August 2017

Hitoshi Masuda

1 reference

20 August 2017

Iwao Fukui

1 reference

20 August 2017

Junji Yonese

1 reference

20 August 2017

11 July 2016

1 reference

International Journal of Clinical Oncology

20 August 2017

1 reference

20 August 2017

1 reference

20 August 2017

1 reference

20 August 2017

1191-1195

1 reference

Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer

20 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5124438

Denosumab: a new option in the treatment of bone metastases from urological cancers

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5124438

A single-dose study of denosumab in patients with various degrees of renal impairment

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5124438

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5124438

Zoledronic acid - a multiplicity of anti-cancer action

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5124438

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5124438

Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5124438

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5124438

Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5124438

Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5124438

Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5124438

Renal Failure with the Use of Zoledronic Acid

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5124438

Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5124438

2 September 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1019-4

Metastatic Pattern of Bladder Cancer: Correlation With the Characteristics of the Primary Tumor

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27402103

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Treatment outcome and prognostic factors in renal cell cancer patients with bone metastasis

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27402103

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10147-016-1019-4

1 reference

20 August 2017

1 reference

20 August 2017

PubMed publication ID

27402103

1 reference